Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study

Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study

Abstract Introduction The EVEREST II study previously reported that intravitreally administered ranibizumab (IVR) combined with photodynamic therapy (PDT) achieved superior visual gain and polypoidal lesion closure compared to IVR alone in patients with polypoidal choroidal vasculopathy (PCV). This...

Full description

Bibliographic Details
Main Authors: Kelvin Yi Chong Teo, Kyu-Hyung Park, Nor Fariza Ngah, Shih-Jen Chen, Paisan Ruamviboonsuk, Ryusaburo Mori, Nagako Kondo, Won Ki Lee, Rajesh Rajagopalan, Ryo Obata, Ian Y. H. Wong, Caroline Chee, Hiroko Terasaki, Tetsuju Sekiryu, Shih-Chou Chen, Yasuo Yanagi, Shigeru Honda, Timothy Y. Y. Lai, Chui Ming Gemmy Cheung
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-02-01
Series:Ophthalmology and Therapy
Subjects:
Polypoidal choroidal vasculopathy
Long-term outcomes
EVEREST II
Anti-vascular endothelial growth factor (VEGF) therapies
BCVA
Online Access:https://doi.org/10.1007/s40123-024-00888-0

Internet

https://doi.org/10.1007/s40123-024-00888-0

Similar Items